Equity Vii L.P. Spectrum Sells 10,677 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $4.09, for a total value of $43,668.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.

GoodRx Stock Down 1.1%

NASDAQ GDRX traded down $0.05 on Thursday, reaching $4.48. The company had a trading volume of 1,394,918 shares, compared to its average volume of 1,387,632. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -149.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.16. GoodRx Holdings, Inc. has a 1-year low of $3.68 and a 1-year high of $9.26. The company's fifty day moving average is $4.25 and its 200-day moving average is $4.53.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The firm had revenue of $202.97 million for the quarter, compared to the consensus estimate of $202.25 million. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The business's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.08 earnings per share. On average, research analysts forecast that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GoodRx

Several hedge funds and other institutional investors have recently bought and sold shares of GDRX. National Bank of Canada FI boosted its holdings in GoodRx by 34.9% in the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after acquiring an additional 2,151 shares in the last quarter. Citizens Financial Group Inc. RI bought a new position in GoodRx during the first quarter valued at about $44,000. Jump Financial LLC bought a new stake in shares of GoodRx in the 1st quarter worth approximately $49,000. RPO LLC purchased a new stake in GoodRx in the 4th quarter worth about $52,000. Finally, Versor Investments LP bought a new stake in GoodRx during the 4th quarter valued at $54,000. Institutional investors and hedge funds own 63.77% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on GDRX shares. Wells Fargo & Company cut their price objective on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. The Goldman Sachs Group cut their target price on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Truist Financial reduced their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Finally, UBS Group reduced their target price on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, GoodRx currently has a consensus rating of "Moderate Buy" and an average target price of $6.55.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.